Affimed (NASDAQ:AFMD) Sees Large Decrease in Short Interest

Affimed (NASDAQ:AFMD) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 602,500 shares, a decrease of 14.9% from the February 28th total of 708,100 shares. Approximately 4.6% of the company’s shares are sold short. Based on an average daily trading volume, of 186,000 shares, the short-interest ratio is presently 3.2 days.

Affimed Stock Down 1.8 %

AFMD stock opened at $0.71 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. The business has a fifty day simple moving average of $0.97 and a 200-day simple moving average of $2.04. Affimed has a 52 week low of $0.70 and a 52 week high of $8.95.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently added to or reduced their stakes in AFMD. Jane Street Group LLC purchased a new stake in shares of Affimed during the 3rd quarter worth about $44,000. Point72 Asset Management L.P. lifted its position in Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares in the last quarter. Intellectus Partners LLC grew its stake in Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 32,053 shares during the period. Northern Trust Corp acquired a new stake in shares of Affimed in the fourth quarter worth $218,000. Finally, FMR LLC raised its stake in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 4,086 shares during the period. 30.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on AFMD shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Affimed in a report on Tuesday, December 10th. StockNews.com initiated coverage on Affimed in a research note on Tuesday. They issued a “sell” rating for the company. Finally, Wells Fargo & Company decreased their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.